Let me start by saying that I'm not an expert on medical devices. Nor do I play one on TV. But like Warren Buffett, I want to own great businesses, and sometimes it's not necessary to know the nitty-gritty details of the next product launch to know when a company is simply very, very good at doing what it does. And I think Medtronic
Of course, finding a strong business is only half the battle -- you also need to know when it's priced attractively enough to buy. Does Medtronic pass that test? Let's take a closer look.
As I outlined in a previous article, a good way to get a baseline for growth expectations is to check on what Wall Street analysts expect and how fast the company has actually grown in the past.
Annual Growth Rate
|Last 12 months||(2.7%)|
Source: Capital IQ, a Standard & Poor's company. Historical growth based on operating earnings.
This isn't an overly encouraging picture. The growth over the past decade has been swell, but it fell markedly during the three- and five-year periods and the company actually saw operating earnings shrink over the past 12 months. Not only has the company faced tough times brought on by the tepid economy, but it's also seen growth slow drastically for its largest product segments.
Looking ahead, the company expects that products that have a peppier growth trajectory will become a bigger part of the revenue mix, which will boost overall growth. The company also has footholds in faster-growing emerging markets, and it expects that they will also contribute to a higher growth rate over time.
It's also notable that the Medtronic has steadily bought back shares over the years. Over the past decade, it reduced its share count by an average of 1.2% per year. Over the past five years, that's bumped up to 2.3%. That's great for shareholders because fewer shares mean more earnings are divvied up to each share.
Taking a conservative view of the company's future growth and adding in some impact from the ever-falling share count, I assumed that Medtronic would grow earnings per share at a 5% rate over the next five years. For my upside case, I used 7%, and I dropped it to 3% for my downside case.
Pinning down valuation
Valuations are a moving target that can be tough to predict, but, as with growth above, using a range of values can give us a view of our potential returns without requiring a Miss Cleo-type prescience.
In creating our range, a good place to start is where the stock is trading right now and what its historical trading range has been. Right now, Medtronic's stock changes hands at 13.7 times trailing earnings. This is all the way at the lower end of the range for the stock, as its annual average earnings multiple was between 15.7 and 66.5 during the stretch between 2000 and 2010.
For broader context we can also look at how similar companies trade.
St. Jude Medical
Source: Capital IQ, a Standard & Poor's company.
Now you'll note that on the basis of analysts' projections, Medtronic is expected to grow at a slower rate than all of the companies above. However, its stock fetches a forward P/E multiple of just 11.3, which I think is a pretty sizable discount given the company's size and quality. Aside from that, I think that to some extent the group as a whole is suffering from an uncertainty discount due to the fog around future health care regulations in the United States. While there may be some merit to that discount, I think there may be more positives in favor of growth -- aging baby boomers, greater consumer access to health insurance, emerging market growth -- that offsets some of that concern.
For my model, I assumed that investors could get very excited and pay as much as 20 times earnings (on a trailing basis) for Medtronic's stock or get even more depressed and pay as little as 12 times. My base case assumes a moderately higher multiple at 15.
Dividends and share count
Our final stop is to consider how much we'll get paid through dividends and whether changes in share count will affect our bottom line.
Above, I already touched on the company's share buybacks. So rather than having to worry that we'll lose value through big share issuances, we get to look forward to a further decline in the number of shares outstanding (which is particularly exciting when the valuation is so low).
The dividend situation at Medtronic is even more exciting. Though its current 2.3% yield isn't enough to attract high-yield snobs, the company has grown its payout by 16% per year over the past decade and 18% per year over the past five years. Even with all of that dividend growth, the company's payout ratio was still just 31% over the past 12 months.
For my model I assumed that dividend growth over the next five years would be between 7% and 18% with a base case of 12%.
The verdict please!
The end result of all of this is the returns we can expect under the various scenarios. Here's what my three scenarios would look like.
Annual Earnings-Per-Share Growth
Annual Dividend Growth
Expected Annual Returns
Source: Author's calculations.
Let's now go back to that question that we started with: Could Medtronic's stock double your money?
Under the optimistic case, the answer is a very definite "yes." The mid-case is a more modest return, but for a quality company like Medtronic, I think that a near-10% annual return is a bit north of fair. And finally, the downside case is far from ideal, but it's not terrible if it's really our likely bottom end.
Of course, the future is an ever-changing picture, so you need to keep on top of what's going on at Medtronic to see which set of numbers the company and stock are able to live up to. And you can do just that by adding the stock to your Foolish watchlist.
The Motley Fool owns shares of Zimmer Holdings and Medtronic. Motley Fool newsletter services have recommended buying shares of Stryker. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer owns shares of Medtronic, but does not have a financial interest in any of the other companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or Facebook. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.